Infiltration Pattern of Locally Advanced ESCC

NCT07567716 · tracked via the Priya Life Science China tracker

Sponsor

Shanghai Chest Hospital

Phase

Observational

Started

2025-10-01

Last updated

2026-05-05

Condition(s) studied

Esophageal Squamous Cell Carcinoma (ESCC)InfiltrationTumour

Investigational drug(s) / intervention(s)

EsophagectomyEsophagectomy

Esophagectomy: Esophagectomy by McKeown method

Esophagectomy: Esophagectomy for ESCC

Study summary

Prospectively collect the pathological records of ESCC patients, and analyse the infiltration pattern of ESCC.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: * cervical or thoracic ESCC * received esophagectomy * preoperative stage T2-3 * no viable multiple lesions * received McKeown esophagectomy Exclusion Criteria: * Incomplete clinical materials

Primary outcome measure(s)

Infiltration pattern — Postoperatively, based on the pathological results of the specimen. Usually, the results will be reported within one month after surgery.
Direct infiltration length of ESCC beyond macroscopic margin and multiple lesions of ESCC.

Trial sites (1)

Facility	City	Region	Status
Shanghai Chest Hospital	Shanghai	China

More Shanghai Chest Hospital trials in China

GGO-dominant PPLs Diagnosis Using CLE and ssRAB-guided Cryobiopsy Starting soon

Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung Cancer Surgery Recruiting

Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma Recruiting

Comparative Efficacy and Safety of Extensive Electro-Anatomical Guided Pulsed Field Ablation Versus Radiofrequency Ablation in Persistent Atrial Fibrillation Starting soon

Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer Recruiting

Other trials for the same condition

Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC Starting soon

NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC Active, not recruiting

Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma Active, not recruiting

A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC Enrolling by invitation

Phase II Study of Induction Chemoimmunotherapy Followed by Radiotherapy and Organ Preservation in Resectable ESCC Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07567716 on ClinicalTrials.gov ↗ ← All trials in China